Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate)

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide is indicated for hypertension, a condition of elevated arterial pressure that benefits from multi‑mechanistic blood‑pressure reduction.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertensive urgency (adjunct): may be used with other agents to achieve target pressures when rapid control is needed.
• Hypertension with fluid retention: combines a diuretic to address volume overload while controlling vascular tone.
• Hypertension in patients who require both an ARB and a calcium‑channel blocker: provides dual pathway blockade for improved efficacy.
• Hypertension resistant to monotherapy: offers a single‑pill option that simplifies dosing and improves adherence.

• The combination tablet works through three complementary mechanisms: olmesartan medoxil blocks angiotensin II type‑1 receptors, preventing vasoconstriction and aldosterone release; amlodipine besilate inhibits L‑type calcium channels in vascular smooth muscle, producing arterial dilation; and hydrochlorothiazide reduces sodium and water reabsorption in the distal convoluted tubule, decreasing plasma volume. Together these actions lower peripheral resistance and cardiac output, producing a sustained antihypertensive effect.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness.
• Peripheral edema, especially of the ankles.
• Headache.
• Fatigue or tiredness.
• Flushing or warmth sensation.
• Increased urination.

Serious or Rare Side Effects

• Severe hypotension or syncope.
• Acute kidney injury or worsening renal function.
• Hyperkalemia or significant electrolyte imbalance.
• Angio‑edema involving the face, lips or airway.
• Hepatic dysfunction with elevated transaminases.
• Severe skin reactions such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: check serum potassium and sodium before and during treatment.
• Cardiovascular status: monitor for symptomatic hypotension, especially in volume‑depleted patients.
• Pregnancy: avoid use; drug class is contraindicated in the second and third trimesters.
• Concomitant drugs: review for potential additive blood‑pressure lowering effects.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide may interact with several medicines; careful review is advised.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalemia and renal impairment.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine exposure.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Lithium: can increase lithium levels, risking toxicity.
• Antidiabetic agents: may require dose adjustment due to enhanced glucose‑lowering effect.
• Alcohol: can potentiate orthostatic hypotension.
• Loop diuretics: may exacerbate electrolyte disturbances when combined with hydrochlorothiazide.